Octreotide depot (GP Pharm SA) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Octreotide depot (GP Pharm SA) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
21
Registered trials
31
Result records
38
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Octreotide depot (GP Pharm SA) can convert its Synthetic peptide profile and SSTR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Octreotide depot (GP Pharm SA) (query alias: octreotide) |
|---|---|
| Modality / target | Synthetic peptide; SSTR; SSTR agonists |
| Highest global status | Approved |
| Originator | GP Pharm SA |
| Active developers | GP Pharm SA |
The MCP disease footprint includes Acromegaly, Bleeding esophageal varices. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT03541447 | Phase 2 | Completed | 20 | Glomerular Filtration Rate (GFR) |
| NCT02874326 | Phase 2 | Unknown status | 15 | The percentage of patients who are full responder, partial responder and non-responder at the end of the treatment period |
| NCT03057509 | Phase 1 | Withdrawn | Not disclosed | Mean Change in SUVmax |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Adjuvant therapy with somatostatin analogs for recurrent gastric neuroendocrine tumors type 1.
Not Applicable; n=35; evaluation: Positive. Reported fields: mDFS = not reached month ( 67 - NR); mDFS = not reached month ( 67 - NR)
Comparison of Combination Low-Dose SRL + Daily Pegvisomant Therapy, Low-Dose SRL + Weekly Pegvisomant Therapy, and High-Dose SRL + Weekly Pegvisomant Therapy
Not Applicable; n=76; evaluation: not stated. Reported fields: Cost Effectiveness(Mean) = 14,261.33 US dollars/month (Standard Deviation, 1,645.49); Cost Effectiveness(Mean) = 22,542.86 US dollars/month (Standard Deviation, 11,158.49); -
EFFICACY AND SAFETY OF OCTREOTIDE FOR THE TREATMENT OF SEVERE RECURRENT GASTROINTESTINAL BLEEDING IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: RESULTS OF A PROSPECTIVE PHASE II MULTICENTER CLINICAL TRIAL
Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Adverse Event: abdominal discomfort = grade I adverse events: abdominal discomfort for less than two days after injection (n = 4)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Octreotide depot (GP Pharm SA) addresses Acromegaly, Bleeding esophageal varices. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 38 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: SSTR records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-06 | Vertex to Acquire Crinetics Pharmaceuticals | Approved | US$1,000.0M stated total |
| 2026-04-20 | 翰宇药业与Torrent再度携手共拓兰瑞肽商业化发展 | Approved | Financial terms not disclosed |
| 2025-12-11 | Everest Medicines Announces Commercialization Service Agreement with Hasten | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
